Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119330 | 1.00 | GAA (0.50) | GAAKDM4ERAB9ANPC1RXFP1 | |
| SCHEMBL117350 | 0.85 | PRKAB2 (0.37) | KDM4E | |
| SCHEMBL117351 | 0.85 | PRKAB2 (0.37) | KDM4E | |
| SCHEMBL21354875 | 0.76 | GAA (0.61) | GAAKDM4ERAB9ANPC1RXFP1 | |
| SCHEMBL117177 | 0.73 | GAA (0.63) | GAAKDM4ERAB9ANPC1RXFP1 | |
| SCHEMBL21356112 | 0.73 | GAA (0.63) | GAAKDM4ERAB9ANPC1RXFP1 | |
| SCHEMBL3545664 | 0.73 | GAA (0.63) | GAAKDM4ERAB9ANPC1RXFP1 | |
| SCHEMBL2770990 | 0.71 | HCRTR1 (0.46) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL28710578 | 0.71 | HCRTR1 (0.46) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL3542064 | 0.71 | GAA (0.60) | GAAKDM4ERAB9ANPC1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2424866-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS -SECRETASE INHIBITORS | High Point Pharmaceuticals, LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126745-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | GAA 30/4885KDM4E 2967/4885RAB9A 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.